A method is provided for reducing weight in a subject by administering an effective amount of a composition comprising omega-3 polyunsaturated fatty acid (PUFA), at least one of L-arginine, L-ornithine, an L-arginine precursor and an L-ornithine precursor, and at least one of a nucleobase, a nucleoside and a nucleic acid. The method can also be used to treat obesity, hyperlipidemia, diabetes and/or hypertension and for improving diathesis, or treating adult disease or disposition to adult disease.

Koide; Masafumi

BBK Bio Corporation

Method for reducing weight in a subject

A single-chain insulin analogue containing a basic side chain at position A8 (Arginine, Histidine, Lysine, or Ornithine), a basic side chain at position B29 (Arginine, Histidine, Lysine, or Ornithine), and a foreshortened C-domain of length 6-11 residues is provided. Residues C1 and C2 of the C-domain have a net negative charge of -1 or -2; C3 is chosen from a group consisting of Gly, Ala, Pro, or Ser; and the remaining C-domain segment is successively derived from the C-domain of IGF-II (RRSR (SEQ ID NO: 18), SRRSR (SEQ ID NO: 17), VSRRSR (SEQ ID NO: 16), RVSRRSR (SEQ ID NO: 15), or SRVSRRSR (SEQ ID NO: 13)). A method of treating a patient with diabetes mellitus or obesity comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient.

ornithine/obezita

Method for reducing weight in a subject

Long-acting single-chain insulin analogues

Najkompletnejšia databáza liečivých bylín podporovaná vedou